Automating NGS Gene Panel Analysis Workflows with Golden Helix

About this webinar

Recorded On: Wednesday, March 3, 2019

In a clinical setting, investing in automatable workflows provides two pay-backs: First, less time is spent by the constraint resource of laboratory staff and medical professionals. Second, and more importantly, the possibilities for errors is reduced. In this webcast, we will cover the full analysis workflow from sequencer to clinical report and how each component can be automated with the Golden Helix clinical stack. Producing high-quality genetic test reports requires the experience of an entire lab and a robust and repeatable process. Join us to see how automation can enable your laboratory to:

  • Automatically start secondary analysis pipelines when new sequence runs are complete
  • Go from FASTQ to BAM and high-quality variants in VCFs hands-off with Sentieon
  • Automatically start VSPipeline to go from raw VCFs to candidate variants
  • Compute coverage and call CNVs alongside small variants with VS-CNV
  • Generate short-list previously scored variants, annotated full candidate variant lists and draft reports with VarSeq and VSClinical

Join us for a tour de force of NGS analytics powered by the Golden Helix VarSeq clinical stack and learn about how each component of your laboratory NGS analysis process may benefit from automation capabilities.

Watch on demand

Please enjoy this webcast recording. Should you have any questions about the content covered, please reach out to our team here.

Download the slides

To download a copy of the slides, click on the LinkedIn icon. This will redirect you to the SlideShare site. From there, you can clip your favorite slides or download the entire deck to your computer.

Love this webcast? Check out more!

Find out how Golden Helix software enables users to harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine.